Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000236 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine Pharmacology Related to Addiction Treatment - 18
A Phase 2 study of Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00000236: Completed Phase 2 study of Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000236 is a Phase 2 study of Opioid-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000236, a Phase 2 study of Opioid-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.
Conditions Studied
Interventions
- DRUG Buprenorphine/naloxone
Study Locations (1)
Vermont
- Treatment Research Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00000236 record still lists
NCT00000236 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00000236 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT00000236 about?
NCT00000236 is a clinical study titled "Buprenorphine Pharmacology Related to Addiction Treatment - 18". The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acce...
What is the current status of trial NCT00000236?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00000236 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT00000236?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00000236?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000236 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2